Interestingly however, in NSCLC, mutations in DNA repair genes such as POLD1, POLE, BRCA2, PRKDC, MSH2, RAD51C, LIG3 and RAD17 were frequently identified in tumours with high mutational burden, the majority of which had a partial response to pembrolizumab (Rizvi et al, 2015). The gene discussed is BRCA2; the disease is neoplasm.